Current perspectives on familial mediterranean fever

Current Opinion in Infectious Diseases

Volumn 22, Issue 3, 2009, Pages 309-315

  Guz, Galip ^a   Kanbay, Mehmet ^b   Ozturk, M Akif ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

Author keywords

Acute phase reactant; Amyloidosis; Familial Mediterranean fever; MEFV; Periodic fever syndrome; Subclinical inflammation

Indexed keywords

AMYLOID A PROTEIN; AZATHIOPRINE; CHEMOKINE; COLCHICINE; CRYOPYRIN; EPRODISATE; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN PYRIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; REGULATOR PROTEIN; SEROTONIN UPTAKE INHIBITOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMYLOID; CYTOSKELETON PROTEIN; MARENOSTRIN;

AMYLOIDOSIS; APOPTOSIS; CELLULAR IMMUNITY; DISEASE SEVERITY; FAMILIAL MEDITERRANEAN FEVER; GENE; GENE MUTATION; INFLAMMATION; KIDNEY AMYLOIDOSIS; MEFV GENE; PATHOGENESIS; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; GENETICS; HUMAN; IMMUNOLOGY; MEDICAL RESEARCH; METABOLISM; PATHOLOGY; PHYSIOLOGY;

AMYLOID; BIOMEDICAL RESEARCH; CYTOSKELETAL PROTEINS; FAMILIAL MEDITERRANEAN FEVER; HUMANS; INFLAMMATION;

EID: 65549097567     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328329d15e     Document Type: Review

References (59)

1. Gang N, Drenth JP, Langevitz P, et al. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol 1999; 26:890-897.
2. Knecht A, de Beer FC, Pras M. Serum amyloid A protein in familial Mediterranean fever. Ann Intern Med 1985; 102:71-72.
3. Samuels J, Aksentijevich I, Torosyan Y, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998; 77:268-297.
4. Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007; 56:1706-1712. An important study claiming that environmental factors affect FMF course.
5. Akdogan A, Calguneri M, Yavuz B, et al. Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol 2006; 48:2351-2353.
6. Bilginer Y, Ozaltin F, Basaran C, et al. Evaluation of intima media thickness of the common and internal carotid arteries with inflammatory markers in familial Mediterranean fever as possible predictors for atherosclerosis. Rheumatol Int 2008; 28:1211-1216. FMF patients should be considered to have an increased risk of early vascular alteration and atherosclerosis. They speculated that common carotid artery intima-media thickness measurement could be recommended as a noninvasive and early diagnostic method.
7. Ozel Demiralp DF, Ekim M, Akar N. The effect of plasminogen activator inhibitor-1-6754G/5G polymorphism on familial mediterranean fever (FMF) disease. Clin Appl Thromb Hemost 2008 [Epub ahead of print].
8. Richards N, Schaner P, Diaz A, et al. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem 2001; 276:39320-39329.
9. Papin S, Cuenin S, Agostini L, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1 beta processing. Cell Death Differ 2007; 14:1457-1466.
10. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005; 17:586-599.
11. Yepiskoposyan L, Harutyunyan A. Population genetics of familial Mediterranean fever: a review. Eur J Hum Genet 2007; 15:911-916.
12. Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 2006; 103: 9982-9987.
13. Fernandes-Alnemri T, Wu J, Yu JW, et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ 2007; 14:1590-1604.
14. Bakkaloglu A. Familial Mediterranean fever. Pediatr Nephrol 2003; 18:853-859.
15. Schwartz T, Langevitz P, Zemer D, et al. Behcet's disease in familial Mediterranean fever: characterization of the association between the two diseases. Semin Arthritis Rheum 2000; 29:286-295.
16. Gershoni-Baruch R, Broza Y, Brik R. Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schonlein purpura. J Pediatr 2003; 143:658-661.
17. Tutar E, Akar N, Atalay S, et al. Familial Mediterranean fever gene (MEFV) mutations in patients with rheumatic heart disease. Heart 2002; 87:568-569.
18. Rabinovich E, Livneh A, Langevitz P, et al. Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene. Ann Rheum Dis 2005; 64:1009-1014.
19. Majeed HA, El-Shanti H, Al-Khateeb MS, Rabaiha ZA. Genotype/phenotype correlations in Arab patients with familial Mediterranean fever. Semin Arthritis Rheum 2002; 31:371-376.
20. Sugiura T, Kawaguchi Y, Fujikawa S, et al. Familial Mediterranean fever in three Japanese patients, and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. Mod Rheumatol 2008; 18:57-59.
21. Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84:1-11.
22. Yigit S, Bagci H, Ozkaya O, et al. MEFV mutations in patients with familial Mediterranean fever in the Black Sea region of Turkey: Samsun experience [corrected]. J Rheumatol 2008; 35:106-113. This article highlights that FMF patients having M694V/M694V carry a high risk for amyloidosis.
23. Grateau G. The relation between familial Mediterranean fever and amyloidosis. Curr Opin Rheumatol 2000; 12:61-64.
24. Konstantopoulos K, Kanta A, Deltas C, et al. Familial Mediterranean fever associated pyrin mutations in Greece. Ann Rheum Dis 2003; 62:479-481.
25. Tchernitchko D, Legendre M, Cazeneuve C, et al. The E148Q MEFV allele is not implicated in the development of familial Mediterranean fever. Hum Mutat 2003; 22:339-340.
26. Topaloglu R, Ozaltin F, Yilmaz E, et al. E148Q is a disease-causing MEFV mutation: a phenotypic evaluation in patients with familial Mediterranean fever. Ann Rheum Dis 2005; 64:750-752.
27. Fidder H, Chowers Y, Ackerman Z, et al. The familial Mediterranean fever (MEVF) gene as a modifier of Crohn's disease. Am J Gastroenterol 2005; 100:338-343.
28. Gershoni-Baruch R, Brik R, Zacks N, et al. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003; 48:1149-1155.
29. Sabbagh AS, Ghasham M, Abdel Khalek R, et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. Mol Biol Rep 2008; 35:447-451.
30. Ben-Chetrit E, Lerer I, Malamud E, et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? Hum Mutat 2000; 15:385-386.
31. Al-Alami JR, Tayeh MK, Najib DA, et al. Familial Mediterranean fever mutation frequencies and carrier rates among a mixed Arabic population. Saudi Med J 2003; 24:1055-1059.
32. Ustek D, Ekmekci C, Oku B, et al. MEFV gene 3′-UTR Alu repeat polymorphisms in patients with familial Mediterranean fever. Clin Exp Rheumatol 2008; 26 (4 Suppl 50):S72-S76. This study highlights that 3′-UTR sequences may have a role in the regulation of MEFV expression.
33. Dizdar O, Kalyoncu U, Karadag O, et al. Macrophage inflammatory protein-1 alpha: a link between innate immunity and familial Mediterranean fever? Cytokine 2007; 37:92-95.
34. Celebi Kobak A, Kobak S, Kabasakal Y, Akarca US. Tumor necrosis factor-alpha gene promoter polymorphism in patients with familial Mediterranean fever. Clin Rheumatol 2007; 26:908-910. This study showed that TNFα/238 and TNFα/308 promoter polymorphisms do not seem to be major genetic risk factors for susceptibility to FMF and severity of the disease.
35. Davtyan TK, Hakobyan GS, Avetisyan SA, Harutyunyan VA. Engaging anti-inflammatory mechanisms and triggering inflammatory effector apoptosis during Familial Mediterranean Fever attack. Inflamm Res 2008; 57: 65-74.
36. Schaner PE, Gumucio DL Familial Mediterranean fever in the postgenomic era: how an ancient disease is providing new insights into inflammatory pathways. Curr Drug Targets Inflamm Allergy 2005; 4:67-76.
37. Bakkaloglu A, Duzova A, Ozen S, et al. Influence of Serum Amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial Mediterranean fever in the Turkish population. J Rheumatol 2004; 31:1139-1142.
38. Mavragani CP, Yiannakouris N, Zintzaras E, et al. Analysis of SAA1 gene polymorphisms in the Greek population: rheumatoid arthritis and FMF patients relative to normal controls. Homogeneous distribution and low incidence of AA amyloidosis. Amyloid 2007; 14:271-275. This study highlights the rarity of the putative amyloidogenic-13T allele in Greek populations may be related to low prevalence of AA amyloidosis development in Greek rheumatoid arthritis patients.
39. Balci-Peynircioglu B, Taskiran ZE, Turel B, et al. The analysis of interleukin-1 receptor antagonist and interleukin-1 beta gene polymorphisms in Turkish FMF patients: do they predispose to secondary amyloidosis? Clin Exp Rheumatol 2008; 26 (4 Suppl 50):S99-S102. This study might be important to show IL-1β-511 (C/T), IL-1β+3953 (C/T) and IL-1Ra VNTR polymorphisms are not associated with the development of amyloid in FMF patients.
40. Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004; 33:273-282.
41. Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007; 119:e474-e483. A consensus statement on the application of colchicine in children and adolescents with FMF was developed on the basis of analysis of literature by experts from Germany and Turkey. Those recommendations are also applicable in adult FMF patients.
42. Erken E, Ozer HT, Bozkurt B, et al. Early suppression of familial Mediterranean fever attacks by single medium dose methyl-prednisolone infusion. Joint Bone Spine 2008; 75:370-372.
43. Tunca M, Akar S, Soyturk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. Clin Exp Rheumatol 2004; 22 (4 Suppl 34):S37-S40.
44. Tweezer-Zaks N, Rabinovich E, Lidar M, Livneh A. Interferon-alpha as a treatment modality for colchicine-resistant familial Mediterranean fever. J Rheumatol 2008; 35:1362-1365.
45. Sayarlioglu H, Erkoc R, Sayarlioglu M, et al. Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases. Rheumatol Int 2006; 27:197-199.
46. Yuksel S, Yalcinkaya F, Acar B, et al. Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 2006; 45:1307-1308.
47. Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol 2004; 10:134-137.
48. Dember LM, Hawkins PN, Hazenberg BP, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356:2349-2360.
49. Tufan A, Babaoglu MO, Akdogan A, et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 2007; 34:1540-1544. An important study investigating the associations between polymorphisms in the drug transporter gene ABCB1 and colchicine resistance in FMF patients.
50. Calguneri M, Apras S, Ozbalkan Z, et al. The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients. Clin Exp Rheumatol 2004; 22 (4 Suppl 34): S41-S44.
51. Mor A, Pillinger MH, Kishimoto M, et al. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol 2007; 13:38-40.
52. Ozgocmen S, Ozcakar L, Ardicoglu O, et al. Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol 2006; 25:83-87.
53. Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with Familial Mediterranean fever resistant to colchicine. Joint Bone Spine 2008; 75:504-505.
54. Gattringer R, Lagler H, Gattringer KB, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 2007; 37:912-914.
55. Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 2007; 66:1545-1546.
56. Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 2008; 167:695-696.
57. Belkhir R, Moulonguet-Doleris L, Hachulla E, et al. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007; 146:825-826.
58. Seyahi E, Ozdogan H, Celik S, et al. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 2006; 24 (5 Suppl 42):S99-S103.
59. Onat AM, Ozturk MA, Ozcakar L, et al. Selective serotonin reuptake inhibitors reduce the attack frequency in familial mediterranean Fever. Tohoku J Exp Med 2007; 211:9-14. An interesting retrospective study suggesting that the addition of selective serotonin reuptake inhibitors to regular colchicine may be useful in colchicine resistant FMF patients.